Format

Send to

Choose Destination
Dialogues Clin Neurosci. 2016 Sep;18(3):267-276.

Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders.

Author information

1
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Abstract

in English, French, Spanish

The development and clinical implementation of personalized medicine crucially depends on the availability of high-quality human biosamples; animal models, although capable of modeling complex human diseases, cannot reflect the large variation in the human genome, epigenome, transcriptome, proteome, and metabolome. Although the biosamples available from public biobanks that store human tissues and cells may represent the large human diversity for most diseases, these samples are not always sufficient for developing biomarkers for patient-tailored therapies for neuropsychiatric disorders. Postmortem human tissues are available from many biobanks; nevertheless, collections of neuronal human cells from large patient cohorts representing the human diversity remain scarce. Two tools are gaining popularity for personalized medicine research on neuropsychiatric disorders: human induced pluripotent stem cell-derived neurons and human lymphoblastoid cell lines. This review examines and contrasts the advantages and limitations of each tool for personalized medicine research.

KEYWORDS:

biobank; iPSC-derived neuron; lymphoblastoid cell line; neuropsychiatric disorder; personalized therapy biomarker

PMID:
27757061
PMCID:
PMC5067144
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dialogues in Clinical Neuroscience Icon for PubMed Central
Loading ...
Support Center